CNS Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $7.7M
- Price
- $5.30
- % Change (Daily % change from the live per-ticker quote feed.)
- 0.00%
- Volume
- 6.2K
About
CNS Pharmaceuticals, Inc. is a clinical-stage pharmaceutical firm primarily focused on developing innovative anti-cancer therapies for tumors affecting the brain and central nervous system. Its primary investigational compound, Berubicin, an anthracycline, is currently progressing through Phase I and II clinical trials as a potential treatment for glioblastoma multiforme, an aggressive form of brain cancer. To bolster its research and development initiatives, the company has entered into several strategic agreements. These include licensing arrangements with Houston Pharmaceuticals, Inc., The University of Texas M.D. Anderson Cancer Center, and Animal Life Sciences, LLC. Additionally, CNS Pharmaceuticals has a development agreement in place with WPD Pharmaceuticals Inc. and a collaborative partnership with Reata Pharmaceuticals, Inc. The company was founded in 2017 and is headquartered in Houston, Texas.
Quick stats
Shares outstanding1.5M
Computed float796.5K
Float / shares54.5%
Cash runway (months)13.7
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001729427
Websitehttps://www.cnspharma.com
AI Summary
AI-generated1/24
minorbullishother
Corero Network Security Strengthens Star Rating in MarketsandMarkets™ 2026 DDoS Protection and Mitigation Market Report
Corero Network Security strengthened its position as a Star in the MarketsandMarkets 2026 DDoS Protection and Mitigation Market report, its second consecutive year in the Stars quadrant.
CEO Carl Herberger framed the recognition as validation of the SmartWall ONE and CORE product lines and customer confidence in keeping networks online.
The release is promotional in nature with no financial figures or material business changes disclosed.